^
Association details:
| Biomarker: | FLT3-TKD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY
Published date:
05/11/2023
Excerpt:
The 1-year OS for patients with a FLT3-ITD mutation or FLT3-TKD mutation were 80% and 100%, respectively...The combination of azacitidine, venetoclax and gilteritinib is safe and effective in pts with FLT3-mutated AML.
Secondary therapy:
azacitidine
Source:
Title:
EFFICACY AND SAFETY OF VENETOCLAX IN COMBINATION WITH GILTERITINIB FOR RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: UPDATED ANALYSES OF A PHASE 1B STUDY
Published date:
05/12/2021
Excerpt:
...43 pts with FLT3mut+ had been enrolled. Median age (range) was 63 years (23–85). FLT3 internal tandem duplications (ITD) were identified in 37 pts (86%) and 6 pts (14%) had only tyrosine kinase domain (TKD) mutations...Ven + Gilt achieved high rates of mCRc in pts with heavily pretreated and prior TKI-exposed R/R FLT3mut+ AML with encouraging molecular clearance rates.
Source:
Title:
333 Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study
Published date:
11/04/2020
Excerpt:
mCRc was achieved by 83.8% of pts...Ven plus Gilt achieved a very high overall rate of marrow and blood blast elimination and mCRc rate (84%) in this expansion cohort of heavily pretreated FLT3mut+ pts...
Trial ID:
